Home delivery of RSV drug proves safe, gains parent approval in pilot study

A small clinical trial shows palivizumab, a respiratory virus preventive, can be safely administered at home rather than in clinics—a shift that could reduce healthcare visits and improve family convenience. The finding may reshape how pediatric immunization programs operate and reduce burden on stretched medical facilities.

Originaltitel: Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents' Preferences